The FDA has approved the first prescription app, Rejoyn, for major depressive disorder (MDD). Developed by Otsuka Pharmaceutical and Click Therapeutics, the app will be available for adults aged 22 and older who are taking antidepressant medications. While the app did not show overwhelming treatment effects in trials, it offers cognitive-behavioral therapy lessons and personalized messaging. The app is expected to be available for download later in 2024. Other mental health apps are available but not FDA-approved. Researchers emphasize the importance of engagement and finding the right app for individual patients. The app’s prescription-only status may aim to allow coverage under health insurance.
Source link
FDA Approves First Prescription App for Depression
